Search Within

Ross Levine

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Journal Article (386)
  2. Meeting Abstract (343)
  3. Editorial (14)
  4. Review (13)
  5. Research Letter (10)
  6. Book Section (3)
  7. Conference Paper (2)
  8. Guidelines (2)
  9. Book Whole (1)
Groups
  1. Adult Leukemia (774)
  2. Center for Hematologic Malignancies (774)
  3. Department of Medicine (774)
  4. Executive Committee, Center for Hematologic Malignancies (774)
  5. GSK Faculty (774)
  6. Hematologic Malignancies, Division of (774)

More Groups

People
  1. Omar Abdel-Wahab (166)
  2. Martin Tallman (131)
  3. Raajit Rampal (87)
  4. Eytan Stein (69)
  5. Maria Arcila (60)
  6. Jay Patel (52)

More People

Years
  1. 2025 (5)
  2. 2024 (32)
  3. 2023 (46)
  4. 2022 (41)
  5. 2021 (44)
  6. 2020 (58)

More Years

Publications
  1. Blood (289)
  2. Leukemia (34)
  3. Cancer Research (27)
  4. Haematologica (24)
  5. Blood Advances (21)
  6. Cancer Cell (21)

More Publications

Publishers
  1. American Society of Hematology (312)
  2. Nature Publishing Group (107)
  3. American Association for Cancer Research (67)
  4. Cell Press (47)
  5. Ferrata Storti Foundation (24)
  6. American Society of Clinical Oncology (22)

More Publishers

Results (774)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Beat AML S8 Group 2: Gilteritinib (GILT) in combination with decitabine (DEC) and venetoclax (VEN) in untreated FLT3 mutated acute myeloid leukemia (AML) patients age ≥60 with high and low variant allele frequency (VAF)
    Meeting Abstract

    Liu, Q.; Welkie, R. L.; Huang, Y.; Swords, R. T.; Lin, T. L.; Koenig, K. L.; Madanat, Y. F.; Patel, P. A.; Collins, R. H.; Blum, W.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • PRC2-mediated apoptosis evasion is a therapeutic target of MDS/AML harboring inv(3)/t(3;3) and-7
    Meeting Abstract

    Kunimoto, H.; Miura, A.; Sagisaka, M.; Ito, M.; Honma, D.; Tsutsumi, S.; Sakuma, T.; Ohashi, T.; Teranaka, H.; Ikeda, J.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A pro-inflammatory gene signature characterizes a better risk aged AML patient group in ECOG-ACRIN Cancer Research Group's clinical trial E3999
    Meeting Abstract

    Neelamraju, Y.; Rapaport, F.; Gandara, J. A.; Dunham, N.; Fan, H.; Lee, T.; Prajapati, S.; Sheridan, C.; Wang, L.; Cripe, L. D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A phase 1b multi-center study of the FLT3 inhibitor gilteritinib in combination with the IDH1 inhibitor ivosidenib or the IDH2 inhibitor enasidenib for patients with relapsed or refractory acute myeloid leukemia who have co-occurring FLT3/IDH1 or FLT3/IDH2 mutations
    Meeting Abstract

    Stein, E. M.; Derkach, A.; Melamed, G.; Block, A.; Kim, J.; Georgieva, G.; Thompson, V.; Levine, R. L.; Intlekofer, A. M.; Abdel-Wahab, O.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Precision lineage deconvolution in mixed phenotype acute leukemia using CITE-seq derived hematopoietic stages identifies lineage dynamics associated with treatment response
    Meeting Abstract

    Dilip, D.; Galera, P.; Nemirovsky, D.; Lallo, M.; Menghrajani, K.; Derkach, A.; Levine, R. L.; Koche, R.; Xiao, W.; Glass, J.
    Blood (2023)

    Fulltext@MSK | Save
  • Loss of CCAAT-enhancer binding protein delta promotes acute myeloid leukemia cell proliferation and survival by upregulating cyclin D1 expression
    Meeting Abstract

    Prajapati, S.; Meydan, C.; Dillon, R.; Dunham, N.; Fan, H.; Gandara, J. A.; Lee, T.; Neelamraju, Y.; Wang, Z.; Zumbo, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A randomized phase 2 trial of 28-day (Arm A) versus 14-Day (Arm B) schedule of venetoclax plus azacitidine in newly diagnosed acute myeloid leukemia patients ≥ 60 years
    Meeting Abstract

    Borate, U. M.; Huang, Y.; Johnson, M. F.; Zeidner, J. F.; Swords, R. T.; Koenig, K. L.; Stein, E. M.; Baer, M. R.; Stock, W.; Madanat, Y. F.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Development of a fully immunocompetent adoptive transfer in vivo model of Npm1(cA); Idh2(R140Q); Flt3(ITD) AML
    Meeting Abstract

    Sharpe, C.; Johnson, M.; Fobare, S.; Elgamal, O. A.; Harrington, B. K.; Mustonen, A.; Bryant, K.; Cheney, C.; Lerma, J. R.; Truxall, J.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Genomic profiles and associated survival prognosticators in Black patients with acute myeloid leukemia
    Meeting Abstract

    Stiff, A.; Nicolet, D.; Fornerod, M.; Kelly, B.; Miller, K.; Mrózek, K.; Boateng, I.; Kain, B. N.; Garfinkle, E.; Hu, E. Y.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia
    Meeting Abstract

    Sirenko, M.; Lee, S.; Sun, Z.; Chaligne, R.; Asimomitis, G.; Brierley, C. K.; Bernard, E.; Cai, S. F.; Myers, R. M.; Nadorp, B.; more...
    Blood (2023)

    Fulltext@MSK | Save